Developing immunobiological products for healthy and safe future

CJSC "RBT" — the developer of own "Betusphere" platform for development of combined adjuvant systems for vaccines with a high safety profile

team members
20+
completed biotech projects
29+
years on the vaccine market
11+
years of experience in R&D of biotech products
40+

The "BetuSphere" platform offers extensive opportunities for the portfolio development and creation of new vaccines

COVID-19 vaccine
"BetuVax"
Co-development
Product
Phase
Influenza vaccine
"TetraFluBet"
Immunimodulator
"BetuSphere"
Against human papillomavirus
HPV vaccine
Against influenza and COVID-19
Combination vaccine
"UltrixCombi"
Co-development
Fast-track
registration
procedure
Fast-track
registration
procedure
Phase II−III
Phase II
Pre-clinical
About
The "RBT" company was established in 2011 for R&D projects in the field of innovative medicines. By combining research experience with successful practical implementation, "RBT" develops challenging projects in the area of biopharmaceuticals.

In 2021, "Artgen Biotech" invested in the development of "RBT" biotechnology platform and creation a number of vaccine drugs against infectious diseases.

In June 2022, the company was assigned the status of a participant in the project for the creation and maintenance of the Skolkovo Innovation Center.
Welcome our team with the successful experience in launching vaccines on the market, attracting investments and biotech IPOs.
  • Igor Krasilnikov
    CEO
    Ph.D, Dr.Sci, Prof., International WHO advisor in vaccine development (Initiative for Vaccine Research program)
  • Artur Isaev
    Strategist, anchor investor
    Founder of "Artgen Biotech", "Gemabank" — the largest russian bank of umbilical cord blood stem cells
  • Mark Kolotov
    CDO
    ex-GSK (UK) Regional Director of Vaccine Department, ex-Boehringer Ingelheim (Germany) Regional Manager, ex-Aventis Pasteur (France) Key Account Manager
  • Taras Ivanishin

    COO

    5+ years of experience in biotech investments. Lomonosov MSU Faculty of Chemistry, Russian Presidential Academy of National Economy and Public Administration
  • Pavel Pogodin
    Director of Legal Affairs
    10+ years of experience in management positions in the state and biotech sector
  • Irina Tcymbarevich
    CTO
    PhD, UZH (imMed), 7+ years of experience in pharmaceutical R&D and technology development
  • Denis Shanygin
    IR Manager
    ex-Biomark Capital USA Project Manager (Russian Branch)
  • Maria Frolova
    Scientific Advisor
    PhD, Heidelberg University
  • Milana Djonovic
    Senior R&D Consultant
    Experience in gene therapy drug development, patenting, bioinformatics
Contacts
CJSC (Closed Joint-Stock Company)
"Biotechnology Developments"
(CJSC RBT)

TIN: 9729341365
RRC: 772901001
PSRN: 1237700160070

Address: 96, pr-kt Vernadskogo "Moscow Center for Healthcare and Innovations"
Phone: +7(993)357-99-03
E-mail: info@rbiotech.ru
By pressing button you confirm your consent to the processing of your personal data and the Confidentiality Policy

Research is carried out with the grant support of the Skolkovo Foundation.

© "Biotechnology Developments", 2023